Addition of cyclosporin A to the combination of mitoxantrone and etoposide to overcome resistance to chemotherapy in refractory or relapsing acute myeloid leukaemia: A randomised phase II trial from HOVON, the Dutch-Belgian Haemato-Oncology Working Group for adults

Leukemia Research

Volumn 28, Issue 10, 2004, Pages 1057-1067

  Daenen, Simon ^a   Van Der Holt, Bronno ^b   Verhoef, Gregor E G ^c   Löwenberg, Bob ^b   Wijermans, Pierre W ^d   Huijgens, Peter C ^e   Van Marwijk Kooy, Rien ^f   Schouten, Harry C ^g   Kramer, Mark H H ^h   Ferrant, Augustin ⁱ   Van Den Berg, Eva ^j   Steijaert, Monique M C ^b   Verdonck, Leo F ^k   Sonneveld, Pieter ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b ERASMUS MEDICAL CENTER   (Netherlands)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d LEYENBURG HOSPITAL   (Netherlands)

^e VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^f ISALA HOSPITAL   (Netherlands)

^g MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^h EEMLAND HOSPITAL   (Netherlands)

ⁱ FREE UNIVERSITY OF BRUSSELS   (Belgium)

^j Free University Hospital ^*  (Netherlands)

^k UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

more..

Author keywords

ABC; acute myeloid leukaemia; AML; ATP binding cassette; BCRP; BM; bone marrow; breast cancer resistance protein; CI; common toxicity criteria; complete remission; confidence intervals; CR; CsA; CTC; cyclosporin A; DFS; disease free survival; EFS; event free survival

Indexed keywords

AMSACRINE; ANTIBIOTIC AGENT; ANTIFUNGAL AGENT; CYCLOSPORIN A; CYTARABINE; ETOPOSIDE; IDARUBICIN; MITOXANTRONE;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ANTIBIOTIC PROPHYLAXIS; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CANCER CHEMOTHERAPY; CANCER RECURRENCE; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG ERUPTION; DRUG FEVER; DRUG SAFETY; EAR NOSE THROAT DISEASE; FEMALE; FOLLOW UP; GASTROINTESTINAL INFECTION; HEADACHE; HEMATOLOGIC DISEASE; HUMAN; HYPERBILIRUBINEMIA; INFECTION; KIDNEY DISEASE; LIVER DISEASE; LUNG INFECTION; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SEPTICEMIA; SIDE EFFECT; SKIN INFECTION; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME; UROGENITAL TRACT INFECTION;

ACUTE DISEASE; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CYCLOSPORINE; DRUG RESISTANCE, NEOPLASM; ETOPOSIDE; FEMALE; HUMANS; LEUKEMIA, MYELOID; MALE; MIDDLE AGED; MITOXANTRONE; PROGNOSIS; RECURRENCE; REGRESSION ANALYSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 20844440529     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2004.03.001     Document Type: Article

References (46)

1. Curt G.A., Clendeninn N.J., Chabner B.A. Drug resistance in cancer. Cancer Treat. Rep. 68:1984;87-99
2. Pastan I., Gottesman M. Multiple-drug resistance in human cancer. N. Engl. J. Med. 316:1987;1388-1393
3. Juliano R.L., Ling V. A surface glycoprotein modulating drug permeability in Chinese hamster ovary cell mutants. Biochim. Biophys. Acta. 455:1976;152-162
4. Cornwell M.M., Safa A.R., Felsted R.L., Gottesman M.M., Pastan I. Membrane vesicles from multidrug-resistant human cancer cells contain a specific 150- to 170 kDa protein detected by photoaffinity labeling. Proc. Natl. Acad. Sci. U.S.A. 83:1986;3847-3850
5. Skovsgaard T. Mechanisms of resistance to daunorubicin in Ehrlich ascites tumor cells. Cancer Res. 38:1978;1785-1791
6. Cole S.P.C., Bhardwaj G., Gerlach J.H., Mackie J.E., Grant C.E., Almquist K.C., et al. Overexpression of a transporter gene in a multidrug-resistant human lung cancer cell line. Science. 258:1992;1650-1654
7. Kool M., de Haas M., Scheffer G.L., Scheper R.J., van Eijck M.J.T., Juijn J.A., et al. Analysis of expression of cMOAT (MRP2), MRP3, MRP4 and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res. 57:1997;3537-3547
8. Ross D.D., Karp J.E., Chen T.T., Doyle L.A. Expression of breast cancer resistance protein in blast cells from patients with acute leukemia. Blood. 96:2000;365-368
9. r 110,000 vesicular protein in non-P-glycoprotein-mediated multidrug resistance. Cancer Res. 53:1993;1475-1479
10. Fojo A.T., Ueda K., Slamon D.J., Poplack D.G., Gottesman M.M., Pastan I. Expression of a multidrug resistance gene in human tumors and tissues. Proc. Natl. Acad. Sci. U.S.A. 84:1987;265-269
11. Cordon-Cardo C., O'Brien J.P., Casals D., Rittman-Grauer L., Biedler J.L., Melamed M.R., et al. Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites. Proc. Natl. Acad. Sci. U.S.A. 86:1989;695-698
12. Chaudhary P.M., Roninson I.B. Expression and activity of P-glycoprotein, a multidrug efflux pump, in human hematopoietic stem cells. Cell. 66:1991;85-94
13. List A.F., Spier C.M., Cline A., Doll D.C., Garewal H., Morgan R., et al. Expression of the multidrug resistance gene product (P-glycoprotein) in myelodysplasia is associated with a stem cell phenotype. Brit. J. Haematol. 78:1991;28-34
14. Drach D., Zhao S., Drach J., Mahadevia R., Gattringer C., Huber H., et al. Subpopulations of normal peripheral blood and bone marrow cells express a functional multidrug resistant phenotype. Blood. 80:1992;2729-2734
15. Chaudhary P.M., Mechetner E.B., Roninson I.B. Expression and activity of the multidrug resistance P-glycoprotein in human peripheral blood lymphocytes. Blood. 80:1992;2735-2739
16. Te Boekhorst P.A.W., de Leeuw K., Schoester M., Wittebol S., Nooter K., Hagemeijer A., et al. Predominance of functional multidrug resistance (MDR-1) phenotype in CD34+ acute myeloid leukemia cells. Blood. 82:1993;3157-3162
17. Michieli M., Damiani D., Ermacora A., Masolini P., Raspadori D., Visani G., et al. P-glycoprotein, lung resistance-related protein and multidrug resistance associated protein in de novo acute non-lymphocytic leukaemias: biological and clinical implications. Brit. J. Haematol. 104:1999;328-335
18. Leith C.P., Chen I.M., Kopecky K.J., Appelbaum F.R., Head D.R., Godwin J.E., et al. Correlation of multidrug resistance (MDR1) protein expression with functional dye/drug efflux in acute myeloid leukemia by multiparameter flow cytometry: identification of discordant MDR-/efflux+ and MDR1+/efflux-cases. Blood. 86:1995;2329-2342
19. Willman C.L. Immunophenotyping and cytogenetics in older adults with acute myeloid leukemia: significance of expression of the multidrug resistance gene-1 (MDR1). Leukemia. 10(suppl 1):1996;S33-35
20. Van den Heuvel-Eibrink M.M., Wiemer E.A., de Boevere M.J., van der Holt B., Vossebeld P.J., Pieters R., et al. MDR1 gene-related clonal selection and P-glycoprotein function and expression in relapsed or refractory acute myeloid leukemia. Blood. 97:2001;3605-3611
21. Marie J.P., Bastie J.N., Coloma F., Faussat Suberville A.M., Delmer A., Rio B., et al. Cyclosporin A as a modifier agent in the salvage treatment of acute leukemia (AL). Leukemia. 7:1993;821-824
22. Legrand O., Simonin G., Beauchamp-Nicoud A., Zittoun R., Marie J.P. Simultaneous activity of MRP1 and Pgp is correlated with in vitro resistance to daunorubicin and with in vivo resistance in adult acute myeloid leukemia. Blood. 94:1999;1046-1056
23. Van der Kolk D.M., de Vries E.G., van Putten W.J., Verdonck L.F., Ossenkoppele G.J., Verhoef G.E., et al. P-glycoprotein and multidrug resistance protein activities in relation to treatment outcome in acute myeloid leukemia. Clin. Cancer Res. 6:2000;3205-3214
24. List A.F., Spier C.S., Grogan T.M., Johnson C., Roe D.J., Greer J.P., et al. Overexpression of the major vault transporter protein lung-resistance protein predicts treatment outcome in acute myeloid leukemia. Blood. 87:1996;2464-2469
25. Tsuruo T., Iida H., Tsukagoshi S., Sakurai Y. Increased accumulation of vincristine and adriamycin in drug-resistant P388 tumor cells following incubation with calcium antagonists and calmodulin inhibitors. Cancer Res. 42:1982;4730-4733
26. Slater L.M., Sweet P., Stupecky M., Gupta S. Cyclosporin A reverses vincristine and daunorubicin resistance in acute lymphatic leukemia in vitro. J. Clin. Invest. 77:1986;1405-1408
27. Sonneveld P. Multidrug resistance in haematological malignancies. J. Intern. Med. 247:2000;521-534
28. List A.F., Spier C., Greer J., Wolff S., Hutter J., Dorr R., et al. Phase I/II trial of cyclosporine as a chemotherapy-resistance modifier in acute leukemia. J. Clin. Oncol. 11:1993;1652-1660
29. List A.F., Kopecky K.J., Willman C.L., Head D.R., Persons D.L., Slovak M.L., et al. Benefit of cyclosporine modulation of drug resistance in patients with poor-risk acute myeloid leukemia: a Southwest Oncology Group study. Blood. 98:2001;3212-3220
30. Tallman M.S., Lee S., Sikic B.I., Paietta E., Wiernik P.H., Bennett J.M., et al. Mitoxantrone, etoposide, and cytarabine plus cyclosporine for patients with relapsed or refractory acute myeloid leukemia: an Eastern Cooperative Oncology Group pilot study. Cancer. 85:1999;358-367
31. Liu Yin J.A., Wheatley K., Rees J.K.H., Burnett A.K. On behalf of the UK, with or without cyclosporine, in refractory/relapsed acute myeloid leukaemia (AML): results of the UK Medical Research Council AML-R trial. Brit. J. Haematol. 113:2001;713-726
32. Dahl G.V., Lacayo N.J., Brophy N., Dunussi-Joannopoulos K., Weinstein H.J., Chang M., et al. Mitoxantrone, etoposide, and cyclosporine therapy in pediatric patients with recurrent or refractory acute myeloid leukemia. J. Clin. Oncol. 18:2000;1867-1875
33. Daenen S., Löwenberg B., Sonneveld P., van Putten W.L.J., Verhoef G., Verdonck L.F., et al. on behalf of the Dutch Hematology-Oncology Working Group for Adults (HOVON). Efficacy of etoposide and mitoxantrone in patients with acute myelogenous leukemia refractory to standard induction therapy and intermediate-dose cytarabine with amsidine. Leukemia. 8:1994;6-10
34. Bow E.J., Sutherland J.A., Kilpatrick M.G., Williams G.J., Clinch J.J., Shore T.B., et al. Therapy of untreated acute myeloid leukemia in the elderly: remission-induction using a non-cytarabine-containing regimen of mitoxantrone plus etoposide. J. Clin. Oncol. 14:1996;1345-1352
35. NCI Common Toxicity Criteria. NCI Cancer Treatment Evaluation Program Home Page. http://ctep.cancer.gov/reporting/ctc.html.
36. Hiddemann W., Aul C., Maschmeyer G., Schonrock-Nabulsi R., Ludwig W.D., Bartholomaus A., et al. High-dose versus intermediate dose cytosine arabinoside combined with mitoxantrone for the treatment of relapsed and refractory acute myeloid leukemia: results of an age adjusted randomized comparison. Leuk. Lymphoma. 10(suppl):1993;133-137
37. Kern W., Aul C., Maschmeyer G., Schonrock-Nabulsi R., Ludwig W.D., Bartholomaus A., et al. Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: results of an age-adjusted prospective randomized comparison. Leukemia. 12:1998;1049-1055
38. Politi P.M., Arnold S.T., Felsted R.L., Sinha B.K. P-glycoprotein- independent mechanism of resistance to VP-16 in multidrug-resistant tumor cell lines: pharmacokinetic and photoaffinity labeling studies. Mol. Pharmacol. 37:1990;790-796
39. Sehested M., Friche E., Jensen P.B., Demant E.J. Relationship of VP-16 to the classical multidrug resistance phenotype. Cancer Res. 52:1992;2874-2879
40. Maia R.C., Carrico M.K., Klumb C.E., Noronha H., Coelho A.M., Vasconcelos F.C., et al. Clinical approach to circumvention of multidrug resistance in refractory leukemic patients: association of cyclosporin A with etoposide. J. Exp. Clin. Cancer Res. 16:1997;419-424
41. Pastan I., Gottesman M.M., Ueda K., Lovelace E., Rutherford A.V., Willingham M.C. A retrovirus carrying an MDR1 cDNA confers multidrug resistance and polarized expression of P-glycoprotein in MDCK cells. Proc. Natl. Acad. Sci. U.S.A. 85:1988;4486-4490
42. Hait W.N., Choudhary S., Srimatkandala S., Murren J.R. Sensitivity of K562 human chronic myelogenous leukemia blast cells transfected with a human multidrug resistance cDNA to cytotoxic drugs and differentiating agents. J. Clin. Invest. 91:1993;2207-2215
43. Bartlett N.L., Lum B.L., Fisher G.A., Brophy N.A., Ehsan M.N., Halsey J., et al. Phase I trial of doxorubicin with cyclosporine as a modulator of multidrug resistance. J Clin Oncol. 12:1994;835-842
44. Nooter K., Sonneveld P., Oostrum R., Herweijer H., Hagenbeek T., Valerio D. Overexpression of the mdr1 gene in blast cells from patients with acute myelogenous leukemias is associated with decreased anthracycline accumulation that can be restored by cyclosporin-A. Int. J. Cancer. 45:1990;263-268
45. Larson R.A. Is modulation of multidrug resistance a viable strategy for acute myeloid leukemia? Leukemia. 17:2003;488-491
46. Baer M.C., George S.L., Dodge R.K., O'Loughlin K.L., Minderman H., Caligiuri M.A., et al. Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720. Blood. 100:2002;1224-1232